Psychiatric Times
JULY 1, 2025
Manufacturers of extended-release stimulants that currently do not have a Limitation of Use section in the labeling will be required to add one about this risk, and manufacturers that do already have a Limitation of Use section will be required to revise the labeling to ensure consistent messaging.
Psychiatric Times
JUNE 23, 2025
2 In a press release, NRx Pharmaceuticals said NRX-100 is well positioned for this designation, citing its alignment with national health priorities such as addressing the mental health crisis, innovating treatment for unmet needs, and enhancing domestic drug manufacturing. 1 NRx appears to be committed to the mental health space.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Psychiatric Times
JUNE 30, 2025
A recently filed patent on its preservative-free manufacturing process may further support market exclusivity. Additionally, the company plans to file a citizen petition with the FDA to withdraw preservative-containing forms of ketamine, citing concerns about benzethonium chloride toxicity.
Mad in America
DECEMBER 30, 2023
Borderline Personality Disorder “No Longer Has a Place in Clinical Practice” Image depicts the thoughts and behaviors typically associated with BPD. In June, Micah Ingle wrote that researchers from the UK and New Zealand argue that Borderline Personality Disorder should be abandoned as a diagnostic category.
Mad in America
MARCH 21, 2024
We cited research based on the clinical study reports the manufactures had submitted to drug regulators to get their drugs approved for children and adolescents and other research in our letter. 4,5 I asked Emslie and the manufacturer, Eli Lilly, if they wanted to restore the trials. The fraud was grave.
Expert insights. Personalized for you.
98 
Let's personalize your content